KRAS and neoplasm: Nevertheless, preclinical data as well as clinical data from other tumor entities bearing KRAS mutations give rise to hope for promising combination therapies involving targeted inhibition of the RAS signaling pathway, paving the way for suitable treatment options for patients suffering from PDAC.